Isa N Cruz1, Helen M Coley2, Holger B Kramer3, Thumuluru Kavitah Madhuri2,4, Nur A M Safuwan2, Ana Rita Angelino1, Min Yang5. 1. Department of Pharmaceutical & Biological Chemistry, UCL School of Pharmacy, London, U.K. 2. Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, U.K. 3. Department of Physiology, Anatomy and Genetic, University of Oxford, South Parks Road, Oxford, U.K. 4. Section of Gynaecological Oncology, Royal Surrey County Hospital, Guildford, Surrey, U.K. 5. Department of Pharmaceutical & Biological Chemistry, UCL School of Pharmacy, London, U.K. min.yang@ucl.ac.uk.
Abstract
BACKGROUND: Carboplatin and paclitaxel form the cornerstone of chemotherapy for epithelial ovarian cancer, however, drug resistance to these agents continues to present challenges. Despite extensive research, the mechanisms underlying this resistance remain unclear. MATERIALS AND METHODS: A 2D-gel proteomics method was used to analyze protein expression levels of three human ovarian cancer cell lines and five biopsy samples. Representative proteins identified were validated via western immunoblotting. Ingenuity pathway analysis revealed metabolomic pathway changes. RESULTS: A total of 189 proteins were identified with restricted criteria. Combined treatment targeting the proteasome-ubiquitin pathway resulted in re-sensitisation of drug-resistant cells. In addition, examination of five surgical biopsies of ovarian tissues revealed α-enolase (ENOA), elongation factor Tu, mitochondrial (EFTU), glyceraldehyde-3-phosphate dehydrogenase (G3P), stress-70 protein, mitochondrial (GRP75), apolipoprotein A-1 (APOA1), peroxiredoxin (PRDX2) and annexin A (ANXA) as candidate biomarkers of drug-resistant disease. CONCLUSION: Proteomics combined with pathway analysis provided information for an effective combined treatment approach overcoming drug resistance. Analysis of cell lines and tissues revealed potential prognostic biomarkers for ovarian cancer. Copyright
BACKGROUND:Carboplatin and paclitaxel form the cornerstone of chemotherapy for epithelial ovarian cancer, however, drug resistance to these agents continues to present challenges. Despite extensive research, the mechanisms underlying this resistance remain unclear. MATERIALS AND METHODS: A 2D-gel proteomics method was used to analyze protein expression levels of three humanovarian cancer cell lines and five biopsy samples. Representative proteins identified were validated via western immunoblotting. Ingenuity pathway analysis revealed metabolomic pathway changes. RESULTS: A total of 189 proteins were identified with restricted criteria. Combined treatment targeting the proteasome-ubiquitin pathway resulted in re-sensitisation of drug-resistant cells. In addition, examination of five surgical biopsies of ovarian tissues revealed α-enolase (ENOA), elongation factor Tu, mitochondrial (EFTU), glyceraldehyde-3-phosphate dehydrogenase (G3P), stress-70 protein, mitochondrial (GRP75), apolipoprotein A-1 (APOA1), peroxiredoxin (PRDX2) and annexin A (ANXA) as candidate biomarkers of drug-resistant disease. CONCLUSION: Proteomics combined with pathway analysis provided information for an effective combined treatment approach overcoming drug resistance. Analysis of cell lines and tissues revealed potential prognostic biomarkers for ovarian cancer. Copyright
Authors: M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Dawn P G Fitzpatrick; Jin-Sam You; Kerry G Bemis; Jean-Pierre Wery; James R Ludwig; Mu Wang Journal: Proteomics Clin Appl Date: 2007-01-22 Impact factor: 3.494
Authors: Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman Journal: Cancer Chemother Pharmacol Date: 2013-04-16 Impact factor: 3.333
Authors: Mitchell Acland; Noor A Lokman; Clifford Young; Dovile Anderson; Mark Condina; Chris Desire; Tannith M Noye; Wanqi Wang; Carmela Ricciardelli; Darren J Creek; Martin K Oehler; Peter Hoffmann; Manuela Klingler-Hoffmann Journal: Cancers (Basel) Date: 2022-06-02 Impact factor: 6.575
Authors: Yasmarie Santana-Rivera; Robert J Rabelo-Fernández; Blanca I Quiñones-Díaz; Nilmary Grafals-Ruíz; Ginette Santiago-Sánchez; Eunice L Lozada-Delgado; Ileabett M Echevarría-Vargas; Juan Apiz; Daniel Soto; Andrea Rosado; Loyda Meléndez; Fatima Valiyeva; Pablo E Vivas-Mejía Journal: Am J Transl Res Date: 2020-04-15 Impact factor: 3.940